Premium Nahrungsergänzungsmittel | artgerecht

Molecular Resistance Diagnostics – Methods and Importance

Molecular resistance diagnostics detects genetic changes in pathogens that cause resistance to antibiotics or other drugs, enabling targeted and effective treatment decisions.

Regular tips about health Regular tips about health

Things worth knowing about "Molecular resistance diagnostics"

Molecular resistance diagnostics detects genetic changes in pathogens that cause resistance to antibiotics or other drugs, enabling targeted and effective treatment decisions.

What is molecular resistance diagnostics?

Molecular resistance diagnostics is a modern laboratory technique that identifies genetic changes in pathogens – such as bacteria, viruses, or fungi – that confer resistance to specific medications, particularly antibiotics. Unlike conventional culture-based susceptibility testing, molecular methods can deliver results within a few hours, enabling faster and more precise therapeutic decisions.

Principles and methods

Molecular resistance diagnostics is based on the detection of specific resistance genes or mutations in the genetic material (DNA or RNA) of the pathogen. The most commonly used methods include:

Polymerase Chain Reaction (PCR): Amplification and detection of resistance genes directly from patient samples, often in real time (Real-Time PCR). This is the most widely used approach.
Next Generation Sequencing (NGS): Comprehensive sequencing of the entire pathogen genome to simultaneously identify all known and novel resistance mechanisms.
DNA hybridization and microarray technology: Simultaneous detection of multiple resistance genes on a single chip.
MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry): Enables rapid pathogen identification and, in combined approaches, can also provide insights into resistance patterns.

Clinical applications

Molecular resistance diagnostics is applied across a wide range of medical fields:

Infectious diseases: Detection of multidrug-resistant organisms such as MRSA (Methicillin-resistant Staphylococcus aureus), ESBL-producing Enterobacteriaceae, and VRE (Vancomycin-resistant Enterococci).
Tuberculosis: Rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis, for example using the Xpert MTB/RIF assay.
HIV therapy: Genotypic resistance testing to guide antiretroviral therapy adjustments in cases of treatment failure or before initiating therapy.
Hepatitis B and C: Detection of mutations causing resistance to antiviral medications.
Oncology: Identification of resistance mutations in tumor cells against targeted therapies (e.g., EGFR mutations in lung cancer).

Advantages over conventional methods

Classical phenotypic susceptibility testing requires pathogen cultivation, which can take several days. Molecular diagnostics offers significant advantages in comparison:

Results available within a few hours
High sensitivity and specificity
Detection even from non-culturable pathogens
Simultaneous identification of multiple resistance mechanisms
Contribution to preventing the spread of resistant pathogens

Limitations and challenges

Despite its many advantages, molecular resistance diagnostics also has limitations:

Only known resistance genes can be reliably detected. New or previously uncharacterized resistance mechanisms may be missed.
A positive gene detection confirms the presence of a resistance gene but does not always directly reflect the extent of phenotypic resistance.
High costs for specialized laboratory equipment and infrastructure.
Stringent quality assurance requirements and the need for highly trained personnel.

Importance for patient care and antibiotic stewardship

Molecular resistance diagnostics is a key tool in antibiotic stewardship programs, which promote the rational and responsible use of antibiotics. By rapidly identifying resistance, clinicians are able to:

Switch to an effective medication early in the course of treatment
Reduce the use of broad-spectrum antibiotics
Limit the spread of resistant pathogens in hospitals and the community
Shorten treatment duration and minimize adverse effects

References

World Health Organization (WHO): Global Action Plan on Antimicrobial Resistance. Geneva, 2015. Available at: https://www.who.int/antimicrobial-resistance/global-action-plan/en/
European Centre for Disease Prevention and Control (ECDC): Antimicrobial resistance surveillance in Europe. Stockholm, 2023.
Leclercq R. et al.: EUCAST expert rules in antimicrobial susceptibility testing. Clinical Microbiology and Infection, 2013;19(2):141–160.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.